Jasper Therapeutics, Inc. Reports Significant Net Loss for the Third Quarter 2023
Quarterly Revenue of $17.5 Million Shows Promising Growth
San Francisco-based biotechnology company, Jasper Therapeutics, Inc. [JSPR], released its financial results for the third quarter of 2023 on September 30, 2023. The company reported a significant net loss of $17.5 million for the quarter, reflecting its ongoing investments in research and development. However, the company also revealed a promising quarterly revenue of $19.4 million, indicating strong growth in its operations.
Financial Performance
Despite the net loss, Jasper Therapeutics, Inc. remains focused on advancing its innovative therapies. The company has made substantial investments in research and development, with expenses reaching $14.8 million in the third quarter of 2023, compared to $9.0 million during the same period last year. General and administrative expenses also increased to $4.5 million in the third quarter of 2023, reflecting the company's commitment to expanding its operations.
